Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas

Withdrawn before enrolling · Phase 2

Conditions studied: Soft Tissue Sarcomas

In brief

This trial will assess whether nivolumab alone or nivolumab combined with pazopanib will be associated with an improvement in progression free survival (PFS) at 6 months

Key facts

Study ID
NCT03149120
Run by
NYU Langone Health
People needed
0
Starts
2017-08-01
Expected to finish
2022-06-01
Last updated by the study team
2017-08-22

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.